ClinicalTrials.gg
Sign In
Not yet recruitingNCT07877506Updated Oct 16, 2026

Sodium Bicarbonate Solution Enhances Lens Cleanliness in Magnetically Controlled Capsule Endoscopy

An interventional study of Sodium Bicarbonate Solution in Health Adults, sponsored by Changhai Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Changhai Hospital · Not applicable, Interventional, and Diagnostic

Updated Oct 16, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Magnetically controlled capsule endoscopy (MCE) is a noninvasive alternative to conventional gastroscopy with comparable diagnostic accuracy. However, mucus adherence to the capsule lens during examination can severely impair visualization, and MCE lacks an irrigation mechanism for lens cleaning. Current guidelines provide no intra-procedural recommendations for managing lens soiling. This study aimed to evaluate the efficacy of sodium bicarbonate solution in improving MCE lens cleanliness during gastric examination.

02

Conditions studied

  • Health Adults
03

In context

Lead sponsor

Changhai Hospital is the lead sponsor of 354 studies on the registry; 136 are open to participants now.

Browse Changhai Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Provision of written informed consent
  • Lens cleanliness score of 2 or lower (i.e., score 2 or 1) on a 4-point scale during MCE examination before intervention

Exclusion criteria

Exclusion Criteria:

  • Dysphagia
  • Suspected or confirmed esophageal stenosis or obstruction
  • Overt gastrointestinal bleeding
  • Poor general condition
  • Pregnancy or suspected pregnancy
  • Known allergy to sodium bicarbonate
  • Current participation in another clinical study
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Sodium Bicarbonate Solution

    Procedure: Sodium Bicarbonate Solution

Interventions

  • ProcedureSodium Bicarbonate Solution

    The capsule lens is aimed at the cardia. Use 30ml of 1% sodium bicarbonate solution (food-grade baking soda) to clean the capsule lens.

06

What researchers measure

Primary outcomes

  1. The proportion of study participants with a baseline lens cleanliness score ≤2 who achieved good or excellent lens cleanliness (cleanliness score ≥3) at the cardia after cleansing with sodium bicarbonate solution, defined as the cleansing success rate.

    Time frame: From enrollment to the end of treatment at 2 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 16, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07877506
Lead sponsor
Changhai Hospital
Responsible party
Zhuan Liao (Clinical Professor, Changhai Hospital) — Principal investigator
First posted
Oct 16, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

Zhuan Liao
Contact
zhuanleo@126.com
8613061921980

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Changhai Hospital →

Start the discussion